Edrophonium Ion en es it fr

Edrophonium Ion Brand names, Edrophonium Ion Analogs

Edrophonium Ion Brand Names Mixture

  • No information avaliable

Edrophonium Ion Chemical_Formula


Edrophonium Ion RX_link


Edrophonium Ion fda sheet

Edrophonium_Ion FDA

Edrophonium Ion msds (material safety sheet)

Edrophonium Ion Synthesis Reference

No information avaliable

Edrophonium Ion Molecular Weight

352.465 g/mol

Edrophonium Ion Melting Point

No information avaliable

Edrophonium Ion H2O Solubility

No information avaliable

Edrophonium Ion State


Edrophonium Ion LogP


Edrophonium Ion Dosage Forms

Powder for solution

Edrophonium Ion Indication

For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.

Edrophonium Ion Pharmacology

Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol.

Edrophonium Ion Absorption

No information avaliable

Edrophonium Ion side effects and Toxicity

Symptoms of overdose are extensions of its dose-limiting pharmacologic effects and include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Most events were self-limiting and resolved with reduction or withholding of epoprostenol. Single intravenous doses at 10 and 50 mg/kg (2703 and 27,027 times the recommended acute phase human dose based on body surface area) were lethal to mice and rats, respectively. Symptoms of acute toxicity were hypoactivity, ataxia, loss of righting reflex, deep slow breathing, and hypothermia.

Edrophonium Ion Patient Information

Edrophonium Ion Organisms Affected

Humans and other mammals